PCOS: Why "Just Take Birth Control" Is Not Enough

The Most Common Endocrine Disorder in Women

Polycystic ovary syndrome (PCOS) affects 8-13% of reproductive-age women, making it the most prevalent endocrine disorder in women (Bozdag et al., Human Reproduction Update, 2016). Up to 70% of cases remain undiagnosed. The average time from symptom onset to diagnosis exceeds 2 years, with patients seeing an average of 3 physicians before receiving the correct diagnosis.

Rotterdam Criteria: Establishing the Diagnosis

PCOS is diagnosed when at least 2 of 3 criteria are present (Rotterdam Consensus, 2003):

1. Oligo-ovulation or anovulation — irregular cycles (>35 days) or amenorrhea 2. Clinical and/or biochemical hyperandrogenism — acne, hirsutism, alopecia, elevated free testosterone or DHEA-S 3. Polycystic ovarian morphology on ultrasound — 12 or more follicles measuring 2-9 mm and/or ovarian volume >10 mL

Important: other causes of hyperandrogenism must be excluded — congenital adrenal hyperplasia (17-OH progesterone), Cushing syndrome (cortisol), prolactinoma (prolactin), hypothyroidism (TSH).

Insulin Resistance: The Root Cause in 70% of Patients

Insulin resistance is present in 70-80% of women with PCOS (both obese and lean). The mechanism: excess insulin stimulates ovarian theca cells to overproduce androgens (testosterone, androstenedione) and reduces SHBG, increasing bioavailable free testosterone.

Diagnostic workup for insulin resistance in PCOS: - Fasting insulin (>10 uIU/mL suspicious, >15 highly suggestive) - HOMA-IR index = glucose (mmol/L) x insulin (uIU/mL) / 22.5 (normal <2.0, PCOS often >3.0) - Oral glucose tolerance test (OGTT) with insulin — 0, 30, 60, 120 minutes - HbA1c — for chronic glycemia assessment

Anti-Mullerian Hormone (AMH): A PCOS Biomarker

AMH is produced by granulosa cells of preantral and small antral follicles. In PCOS, AMH is elevated 2-3 fold (>4.7 ng/mL) due to the large number of immature follicles. Dewailly et al. (Human Reproduction Update, 2014) proposed AMH as an additional diagnostic criterion.

Why Birth Control Does Not Solve the Problem

Combined oral contraceptives (COCs) are the standard first-line treatment in gynecological practice. They suppress ovarian androgens, regulate cycles, improve acne and hirsutism, and protect the endometrium.

However, COCs do NOT address insulin resistance. In fact, Diamanti-Kandarakis et al. (JCEM, 2003) showed that certain COCs worsen insulin resistance. Upon discontinuation, all symptoms return — often more severely.

Comprehensive PCOS Treatment Protocol

### 1. Inositol (Myo-inositol + D-chiro-inositol)

Myo-inositol (MI) is a second messenger in insulin signaling. MI deficiency is a key mechanism of insulin resistance in PCOS. Meta-analysis by Unfer et al. (Gynecological Endocrinology, 2017): MI 4,000 mg/day + DCI 110 mg/day (40:1 ratio) significantly reduces testosterone, improves ovulation, and lowers fasting insulin. Recommended: MI 2,000 mg + DCI 55 mg twice daily.

### 2. Metformin

An insulin sensitizer that reduces hepatic glucose production. Cochrane meta-analysis (Morley et al., 2017): metformin improves ovulation, reduces androgens, and decreases weight in PCOS. Starting dose: 500 mg, titrated to 1,500-2,000 mg/day.

### 3. Spironolactone

An aldosterone antagonist with anti-androgenic activity. Blocks androgen receptors and inhibits 5-alpha reductase. Dosage: 50-200 mg/day. Effects on acne and hirsutism appear after 3-6 months. Contraception is mandatory (teratogenic risk).

### 4. Lifestyle Management

Nutrition: Mediterranean diet with low glycemic index. Meta-analysis in Nutrients (2020): reducing dietary GI significantly decreases fasting insulin, androgens, and improves ovulation in PCOS.

Exercise: 150 minutes moderate aerobic activity plus 2 resistance training sessions per week. A 5-10% weight loss normalizes ovulation in 55-80% of overweight women with PCOS (Moran et al., Human Reproduction Update, 2011).

Supplements: - Vitamin D3: 2,000-4,000 IU/day (deficiency in 67-85% of PCOS patients) - Omega-3: 2,000 mg EPA+DHA (reduces inflammation and triglycerides) - Berberine: 500 mg three times daily (insulin sensitizer comparable to metformin) - N-acetylcysteine (NAC): 1,800 mg/day (improves ovulation and insulin sensitivity)

Frequently Asked Questions

Can you get pregnant with PCOS? Yes. Correcting insulin resistance (inositol + metformin + lifestyle) restores ovulation in most women. If needed, letrozole is the preferred ovulation induction agent (superior to clomiphene per NEJM meta-analysis, 2014).

Is PCOS permanent? PCOS is a chronic condition with genetic predisposition. However, symptoms can be controlled and minimized by addressing insulin resistance.

Should PCOS be treated if pregnancy is not planned? Yes. Untreated PCOS increases risk of type 2 diabetes (5-8 fold), cardiovascular disease, endometrial hyperplasia and cancer, depression, and metabolic syndrome.

Is inositol better than metformin? Inositol is better tolerated (fewer GI side effects), available without prescription, and comparably effective. The optimal strategy is combining both.

*This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.*

🌀

Rotterdam Phenotypes: Four Subgroups Under One Diagnosis

The Rotterdam consensus defines PCOS by any two of three criteria, which mathematically yields four phenotypes. The 2023 International Evidence-Based Guideline endorses phenotype-specific risk stratification because metabolic burden differs substantially across subgroups [PMID: 37580687^[1]].

Phenotype A (classic/full PCOS) combines hyperandrogenism, oligo-anovulation, and polycystic ovarian morphology. This is the most metabolically severe form. Prevalence of insulin resistance and metabolic syndrome is highest here, with HOMA-IR values typically above 3.5 and free androgen index elevations of 2-3 fold over controls [PMID: 24108622^[2]].

Phenotype B has hyperandrogenism and oligo-anovulation without polycystic ovarian morphology on ultrasound. Metabolic risk approaches phenotype A. Patients in this group are frequently misdiagnosed as "not PCOS" because of normal-appearing ovaries on imaging, even though insulin resistance, dyslipidaemia, and androgen excess are fully present.

Phenotype C (ovulatory PCOS) combines hyperandrogenism with polycystic ovarian morphology but preserved regular ovulation. Metabolic risk is intermediate. Cycles are present, fertility may be normal, but acne, hirsutism, and androgenic alopecia drive clinical presentation. Spironolactone and combined oral contraceptives remain first-line; metformin and inositol are added when fasting insulin exceeds 10 μIU/mL or HOMA-IR exceeds 2.5.

Phenotype D (non-hyperandrogenic PCOS) combines oligo-anovulation with polycystic ovarian morphology but without clinical or biochemical hyperandrogenism. Metabolic risk is lowest and closest to controls. Some authors question whether phenotype D represents a distinct disorder from functional hypothalamic anovulation; differentiation requires ruling out energy deficit, hyperprolactinaemia, and thyroid dysfunction [PMID: 33729479^[3]].

Clinical implication: insulin-targeted therapy (inositol, metformin, GLP-1 agonists) yields the largest absolute benefit in phenotypes A and B. Androgen-targeted therapy (spironolactone, combined oral contraceptives, finasteride) gives proportionally larger benefit in phenotype C. Phenotype D often responds to weight restoration and behavioural changes alone. Documenting the phenotype at diagnosis allows the patient and clinician to focus the therapeutic protocol rather than apply a generic PCOS template, and aligns laboratory follow-up with the dominant pathology — fasting insulin and HOMA-IR every 6-12 months for phenotypes A-B, free testosterone and SHBG for phenotype C, and cycle tracking with bone-density review for phenotype D when amenorrhoea persists.

🌀

Letrozole Protocol for Ovulation Induction

Letrozole, an aromatase inhibitor, replaced clomiphene citrate as the first-line ovulation induction agent in PCOS based on the 2014 NIH Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial, which demonstrated higher live-birth rates (27.5% vs 19.1%) and higher cumulative ovulation rates with letrozole. The 2023 international guideline now lists letrozole as recommended first-line and clomiphene as alternative [PMID: 37580687^[1]].

Standard protocol. Letrozole 2.5 mg orally once daily on cycle days 3-7 (five days). If no ovulation occurs by cycle day 21 (confirmed by mid-luteal progesterone below 3 ng/mL), the next cycle dose increases to 5 mg daily. Maximum dose is 7.5 mg daily; doses above 7.5 mg do not improve ovulation rates and increase risk of multifollicular development. Approximately 75-80% of women with PCOS ovulate within three cycles at appropriate dose [PMID: 32034741^[4]].

Monitoring. Mid-luteal progesterone (cycle day 21 in a 28-day cycle, or seven days post-presumed ovulation) confirms response. Transvaginal ultrasound on cycle day 12-14 evaluates dominant follicle size and endometrial thickness; cancellation is recommended if more than three follicles measure ≥16 mm to limit multiple pregnancy risk. Multiple pregnancy rate with letrozole is approximately 3-5%, lower than clomiphene's 7-9% [PMID: 32034741^[4]].

Duration and stopping rules. Six ovulatory cycles is the standard ceiling. If pregnancy has not occurred after six ovulatory cycles, transition to gonadotrophin protocols, laparoscopic ovarian drilling, or in vitro fertilisation is indicated. Continuing letrozole beyond six ovulatory cycles without conception does not improve cumulative pregnancy rates.

Contraindications and safety. Letrozole is contraindicated in pregnancy. Pre-treatment requires negative pregnancy test on cycle day 1-3. Early concerns about teratogenicity from a 2005 abstract were not confirmed in subsequent cohort and registry studies; the rate of major malformations after letrozole-conceived pregnancies is comparable to spontaneous conception [PMID: 18950759^[5]]. Hot flashes, fatigue, and headache are the most common side effects and resolve after the five-day dosing window.

🌀

GLP-1 Receptor Agonists in PCOS: 2023-2025 Evidence

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide as a dual GIP/GLP-1 agonist) were not included in earlier PCOS protocols because the original trials focused on type 2 diabetes and obesity. Recent randomised controlled trials specifically in PCOS populations have expanded the evidence base.

Mechanism in PCOS. GLP-1 agonists reduce body weight (5-15% depending on agent and dose), improve insulin sensitivity, lower fasting insulin, and indirectly reduce ovarian androgen production by removing the hyperinsulinaemic stimulus on theca cells. Direct effects on the ovary remain under investigation.

Liraglutide. A 26-week randomised trial in women with PCOS and obesity demonstrated greater weight loss with liraglutide 3.0 mg daily compared with placebo (5.2% vs 0.5%), with concurrent reductions in free testosterone and improvement in menstrual frequency [PMID: 28438645^[6]]. A separate trial showed restoration of regular menses in approximately 80% of participants after 12 weeks at 1.8 mg daily [PMID: 31905379^[7]].

Semaglutide. A 12-month observational cohort of women with PCOS receiving semaglutide reported mean weight loss of 11-14% and substantial reduction in free androgen index [PMID: 36346732^[8]]. Randomised data in PCOS specifically is more limited than in obesity, but the metabolic improvements are concordant.

Clinical positioning. GLP-1 agonists are appropriate for PCOS patients with body mass index ≥30 kg/m² (or ≥27 with metabolic comorbidity) who have not achieved adequate response to lifestyle intervention with or without metformin. They are not first-line in normal-weight PCOS. The medications are contraindicated in pregnancy and require discontinuation at least two months before planned conception, given the long half-life of semaglutide (approximately one week) and incomplete reproductive safety data. Common side effects (nausea, delayed gastric emptying, constipation) are managed by slow dose escalation; nausea typically attenuates by week 4-6.

Monitoring on therapy. Baseline assessment includes weight, blood pressure, fasting glucose, HbA1c, lipid panel, alanine aminotransferase, and free testosterone. Repeat measurements at 3, 6, and 12 months track response. The androgenic and menstrual benefit lags the weight loss by 2-3 months. The 2023 international guideline notes that GLP-1 agonists may be considered as adjunct therapy in PCOS with obesity but does not yet recommend them as routine first-line [PMID: 37580687^[1]]. Larger PCOS-specific randomised trials are ongoing.

🌀

Endometrial Protection and Surveillance

Chronic anovulation produces unopposed oestrogen exposure of the endometrium. Without periodic progestin opposition, the endometrium undergoes proliferation, then complex hyperplasia, then in some patients endometrial carcinoma. Women with PCOS have a 2.7-fold increased risk of endometrial carcinoma compared with the general population [PMID: 23335732^[9]].

Bleed-interval threshold. The clinical safety threshold is at least four spontaneous or induced withdrawal bleeds per year. Patients with fewer than four cycles per year require active endometrial protection regardless of fertility intent.

Progestin regimens (when contraception is not desired). Cyclic micronised progesterone 200 mg orally at bedtime for 12-14 days every 1-3 months induces a predictable withdrawal bleed. Medroxyprogesterone acetate 10 mg daily for 10-14 days is an alternative. The levonorgestrel-releasing intrauterine system (52 mg, 8-year duration) provides continuous endometrial protection and is the preferred long-term option for patients with abnormal uterine bleeding plus anovulatory PCOS [PMID: 34325430^[10]].

Combined contraceptive option. When contraception is also desired, combined oral contraceptives, the contraceptive ring, or the contraceptive patch all provide endometrial protection. The 2023 guideline notes no specific formulation is superior for PCOS endometrial protection; formulation selection is driven by androgenic profile (drospirenone or cyproterone acetate preferred when hirsutism is dominant) and venous thromboembolism risk [PMID: 37580687^[1]].

Surveillance. Transvaginal ultrasound measurement of endometrial thickness is the first-line evaluation when abnormal bleeding occurs. In a premenopausal patient with PCOS, endometrial thickness ≥12 mm (heterogeneous) or any postmenopausal-pattern thickness ≥4 mm in a transitional patient warrants endometrial biopsy. Endometrial biopsy is also indicated for any intermenstrual bleeding pattern persisting beyond three months, any bleed after six months of amenorrhoea, or any abnormal cytology [PMID: 32621590^[11]]. Routine annual screening of asymptomatic PCOS patients without bleeding abnormalities is not recommended.

Risk modifiers. Obesity, type 2 diabetes, and tamoxifen exposure compound endometrial risk and should lower the threshold for biopsy. Weight loss of 5-10% restores ovulatory cycles in 55-80% of overweight patients and is itself protective. Documentation of bleed intervals — patient cycle calendars, withdrawal-bleed logs after progestin courses — should appear in the chart at each annual visit. A bleed-interval longer than three months in any premenopausal PCOS patient is a trigger for immediate progestin courses or transition to a long-acting endometrial-protective method.

🌀

Adolescent PCOS: Why Adult Criteria Misclassify

Adolescent PCOS diagnosis is the most frequent source of overdiagnosis in endocrine practice. The Rotterdam ultrasound criterion (12+ follicles 2-9 mm, ovarian volume >10 mL) overlaps almost completely with normal post-menarchal ovarian appearance, where multifollicular ovaries are physiological for 2-3 years after first menses.

The 2017 international adolescent PCOS criteria, reaffirmed in 2023, require both persistent oligo-anovulation and clinical or biochemical hyperandrogenism, and explicitly exclude ultrasound from the diagnostic criteria within eight years of menarche [PMID: 17609215^[12], 37580687].

Anovulation criterion in adolescents. Cycle irregularity during the first post-menarchal year is physiological and does not establish anovulation. Persistent oligo-anovulation is defined as: cycles less than 21 days or more than 45 days in the first year post-menarche; cycles less than 21 days or more than 35 days, or fewer than 8 cycles per year, in years 1-3 post-menarche; cycles less than 21 days or more than 35 days from year 3 onward.

Hyperandrogenism in adolescents. Persistent acne unresponsive to topical therapy, moderate-severe hirsutism (modified Ferriman-Gallwey ≥6), or elevated free testosterone above adolescent reference ranges (laboratory-specific) is required. Mild comedonal acne alone is insufficient; mild hirsutism alone is insufficient.

The "at-risk" category. Adolescents with one but not both criteria, or those within the first two years post-menarche, should be classified "at risk for PCOS" rather than diagnosed. These patients warrant interval reassessment at 2-3 years; many will not meet diagnostic criteria at follow-up because cycles regularise spontaneously.

Implication for treatment. Combined oral contraceptives, metformin, and inositol can be offered for symptom management in at-risk adolescents without committing to a permanent PCOS diagnosis. Documenting "at risk" rather than "PCOS" preserves diagnostic accuracy when reassessment occurs after gynaecological maturity, typically at age 18-20.

Anti-Mullerian hormone in adolescents. AMH is elevated in adolescent PCOS as in adult PCOS, but the reference range is not standardised across paediatric assays and overlaps with normal adolescent values. Current consensus does not endorse AMH as a stand-alone diagnostic criterion in adolescents [PMID: 25028408^[13]]. AMH is most useful for confirming ovarian reserve in patients pursuing fertility planning, not for case-finding in symptomatic teenagers.